Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) target, is demonstrating promising outcomes in preliminary clinical studies. Current inquiry https://bookmarkingbay.com/story21343071/retatrutide-emerging-research-and-projected-medical-roles